Fatty Acid-Binding Protein 4 and Risk of Type 2 Diabetes, Myocardial Infarction and Stroke: A Prospective Cohort Study

Intestinal fatty acid binding protein (I-FABP) is released from mature enterocytes when cell membrane integrity is disrupted. This study aimed to prospectively investigate the physiologic significance of early urinary I-FABP and whether it might reflect intestinal compromise in preterm infants. We conducted a prospective cohort study of 100 preterm infants weighing <1250 g and collected serial urine samples at 12, 24, and 48 h after birth. The correlations between initial urinary I-FABP/urinary creatinine (creatinineu) levels and associated factors were analyzed. Among 100 patients, 15 were diagnosed with meconium obstruction of prematurity, and five were diagnosed with necrotizing enterocolitis during the hospital stay. Early urinary I-FABP/creatinineu levels were inversely correlated with both gestational age (Spearman’s rank correlation coefficient (Rs) −0.381, p < 0.01) and birth weight ((Rs) −0.424, p < 0.01). Early urinary I-FABP/creatinineu levels were associated with cord pH ((Rs) −0.436, p < 0.01) and base excess ((Rs) −0.258, p = 0.021). There were significantly positive correlations between early urinary I-FABP/creatinineu levels and the time to full enteral feeding in preterm infants without specific intestinal morbidities. Therefore, a more premature gut with acute perinatal ischemia is expected to exhibit increased I-FABP levels shortly after birth. Because of small sample size, further large-scale studies are needed.

Download Full-text

Circulating Adipocyte Fatty Acid–Binding Protein Concentrations Predict Multiple Mortality Outcomes among Men and Women with Diabetes

Clinical Chemistry ◽

10.1373/clinchem.2018.289157 ◽

2018 ◽

Vol 64 (10) ◽

pp. 1496-1504 ◽

Cited By ~ 5

Author(s):

Chi Ho Lee ◽

Chloe Y Y Cheung ◽

Yu Cho Woo ◽

David T W Lui ◽

Michele M A Yuen ◽

...

Keyword(s):

Type 2 Diabetes ◽

Fatty Acid ◽

Fatty Acid Binding Protein ◽

Independent Predictor ◽

Fatty Acid Binding ◽

Men And Women ◽

Acid Binding Protein ◽

All Cause Mortality

AbstractINTRODUCTIONRaised circulating adipocyte fatty acid–binding protein (AFABP) concentrations are associated with various adverse health conditions. However, their relationship with mortality remains to be defined, especially in view of the sexual dimorphism of circulating AFABP concentrations. Here we investigated prospectively whether serum AFABP concentrations predict multiple mortality outcomes in men and women alike, using a large clinic-based cohort of individuals with type 2 diabetes, a condition with raised AFABP concentrations.METHODSBaseline serum AFABP concentrations were measured in 5305 research participants with a monoclonal antibody-based sandwich immunoassay. The role of circulating AFABP concentrations in predicting mortality outcomes was evaluated by multivariable Cox regression analysis.RESULTSAmong the 5305 participants (59% men) in this study, over a median follow-up of 5 years, there were 512 deaths (19.3 deaths per 1000 person-years). Circulating AFABP concentrations, with higher levels in women at baseline, predicted all-cause mortality (P < 0.001), cardiovascular mortality (P = 0.037), and infection-related deaths (P < 0.002) among all participants. In sex-specific analyses, circulating AFABP concentration was an independent predictor of all-cause mortality in both men and women and a predictor of cancer-related deaths and infection-related deaths in men only. Furthermore, the addition of serum AFABP concentrations improved the time-dependent c statistics in predicting all-cause mortality in participants with type 2 diabetes (P = 0.008).CONCLUSIONSCirculating AFABP concentration was an independent predictor of various mortality outcomes in type 2 diabetes over and above known risk factors of reduced survival in men and women. The role of AFABP as a prognostic biomarker and therapeutic target warrants further investigation.

Download Full-text

Correction: Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner

BMJ Open Diabetes Research & Care ◽

10.1136/bmjdrc-2017-000391corr1 ◽

2017 ◽

Vol 5 (1) ◽

pp. e000391corr1

Keyword(s):

Type 2 Diabetes ◽

Fatty Acid ◽

Fatty Acid Binding Protein ◽

Binding Protein ◽

Independent Manner ◽

Fatty Acid Binding ◽

Glucose Lowering ◽

Acid Binding Protein ◽

Protein Excretion

Download Full-text

Circulating adipocyte fatty acid-binding protein levels predict the development of subclinical atherosclerosis in type 2 diabetes

Journal of Diabetes and its Complications ◽

10.1016/j.jdiacomp.2018.09.001 ◽

2018 ◽

Vol 32 (12) ◽

pp. 1100-1104 ◽

Cited By ~ 2

Author(s):

Yang Xiao ◽

Xiaoyu Xiao ◽

Aimin Xu ◽

Xiaoyan Chen ◽

Weili Tang ◽

...

Keyword(s):

Type 2 Diabetes ◽

Fatty Acid ◽

Fatty Acid Binding Protein ◽

Binding Protein ◽

Subclinical Atherosclerosis ◽

Fatty Acid Binding ◽

Protein Levels ◽

Acid Binding Protein

Download Full-text

Current Metabolic Status Affects Urinary Liver-Type Fatty-Acid Binding Protein in Normoalbuminuric Patients With Type 2 Diabetes

Journal of Clinical Medicine Research ◽

10.14740/jocmr2934w ◽

2017 ◽

Vol 9 (4) ◽

pp. 366-373 ◽

Cited By ~ 3

Author(s):

Hiroyuki Ito ◽

Hitomi Yamashita ◽

Mina Nakashima ◽

Akifusa Takaki ◽

Chiduko Yukawa ◽

...

Keyword(s):

Type 2 Diabetes ◽

Fatty Acid ◽

Fatty Acid Binding Protein ◽

Binding Protein ◽

Metabolic Status ◽

Fatty Acid Binding ◽

Acid Binding Protein

Download Full-text

Fatty acid binding protein 4 inhibitor corrects metabolic disturbance in MKR mouse of Type 2 diabetes

Obesity Research & Clinical Practice ◽

10.1016/j.orcp.2018.11.139 ◽

2019 ◽

Vol 13 (3) ◽

pp. 283

Author(s):

Lili Huang ◽

Weizhuo Dominique Tan ◽

Chengjian Wang ◽

Zhengxiang Huang ◽

Johannes D. Veldhuis ◽

...

Keyword(s):

Type 2 Diabetes ◽

Fatty Acid ◽

Fatty Acid Binding Protein ◽

Binding Protein ◽

Metabolic Disturbance ◽

Fatty Acid Binding ◽

Acid Binding Protein

Download Full-text

Association between adipocyte fatty acid-binding protein with left ventricular remodelling and diastolic function in type 2 diabetes: a prospective echocardiography study

Cardiovascular Diabetology ◽

10.1186/s12933-020-01167-5 ◽

2020 ◽

Vol 19 (1) ◽

Author(s):

Mei-Zhen Wu ◽

Chi-Ho Lee ◽

Yan Chen ◽

Shuk-Yin Yu ◽

Yu-Juan Yu ◽

...

Keyword(s):

Type 2 Diabetes ◽

Fatty Acid ◽

Diastolic Dysfunction ◽

Fatty Acid Binding Protein ◽

Cox Regression ◽

Left Ventricular ◽

Fatty Acid Binding ◽

Acid Binding Protein ◽

Lv Mass

Abstract Background The relationship between adipocyte fatty acid-binding protein (AFABP) and cardiac remodelling has been reported in cross-sectional studies, although with conflicting results. Type 2 diabetes mellitus (T2DM) is associated with left ventricular (LV) hypertrophy and diastolic dysfunction, as well as elevated circulating AFABP levels. Here we investigated prospectively the association between AFABP with the longitudinal changes of cardiac remodelling and diastolic dysfunction in T2DM. Methods Circulating AFABP levels were measured in 176 T2DM patients without cardiovascular diseases (CVD) at baseline. All participants received detailed transthoracic echocardiography both at baseline and after 1 year. Multivariable linear and Cox regression analyses were used to evaluate the associations of circulating AFABP levels with changes in echocardiography parameters and incident major adverse cardiovascular events (MACE), respectively. Results The median duration between baseline and follow-up echocardiography assessments was 28 months. Higher sex-specific AFABP quartiles at baseline were associated with increase in LV mass and worsening of average E/e′ (all P < 0.01). Multivariable linear regression demonstrated that AFABP in the highest quartile was independently associated with both increase in LV mass (β = 0.89, P < 0.01) and worsening of average E/e′ (β = 0.57, P < 0.05). Moreover, multivariable Cox regression analysis showed that elevated baseline circulating AFABP level independently predicted incident MACE (HR 2.65, 95% CI 1.16–6.05, P < 0.05) after adjustments for age, sex, body mass index, glycated haemoglobin, hypertension, dyslipidemia and presence of chronic kidney disease. Conclusion Circulating AFABP level at baseline predicted the development of LV hypertrophy, diastolic dysfunction and MACE in T2DM patients without CVD.

Download Full-text